著者
Hiroko Deguchi Masataka Ikeda Tomomi Ide Tomonori Tadokoro Soichiro Ikeda Kosuke Okabe Akihito Ishikita Keita Saku Shouji Matsushima Hiroyuki Tsutsui
出版者
The Japanese Circulation Society
雑誌
Circulation Journal (ISSN:13469843)
巻号頁・発行日
pp.CJ-19-1039, (Released:2020-03-24)
参考文献数
20

Background:Ischemic preconditioning (IPC) is an effective procedure to protect against ischemia/reperfusion (I/R) injury. Hypoxia-inducible factor-1α (Hif-1α) is a key molecule in IPC, and roxadustat (RXD), a first-in-class prolyl hydroxylase domain-containing protein inhibitor, has been recently developed to treat anemia in patients with chronic kidney disease. Thus, we investigated whether RXD pretreatment protects against I/R injury.Methods and Results:RXD pretreatment markedly reduced the infarct size and suppressed plasma creatinine kinase activity in a murine I/R model. Analysis of oxygen metabolism showed that RXD could produce ischemic tolerance by shifting metabolism from aerobic to anaerobic respiration.Conclusions:RXD pretreatment may be a novel strategy against I/R injury.

言及状況

外部データベース (DOI)

Twitter (4 users, 4 posts, 8 favorites)

$fgen roxadustat https://t.co/3YKy9MYjxj https://t.co/zhCeoE3Xgp
【ラット:HIF-PH阻害薬で心筋が虚血耐性獲得?/ Circ J】 ロキサデュスタットで、心筋虚血・再灌流モデルの梗塞巣サイズが有意に減少。機序として、好気呼吸から無気呼吸への代謝シフトによる虚血耐性獲得が示唆される。 https://t.co/haKtCbQfK8

収集済み URL リスト